Midatech initiates Phase 1 trial of a new hormonal cancer therapy
Category: #health  By Mateen Dalal  Date: 2019-10-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Midatech initiates Phase 1 trial of a new hormonal cancer therapy

Cancer treatment is one of the biggest challenges for the 21st century. There have been many advancements in the field of cancer treatment over the past few years. Clinical trial indeed plays a pivotal role in discovering new drugs, especially for treating serious diseases such as cancer. Numerous organizations across the world are putting in their best efforts to treat cancer effectively.

Midatech Pharma PLC is one such pharmaceutical research and development company that has reportedly started Phase 1 study of MTD201 for patients who are suffering from hormonal-based cancers such as neuroendocrine tumors (NET) and acromegaly.

According to reports, the first batch of healthy volunteers, 14 subjects out of 28, recently attained one dose of Sandostatin 100 microgram/1 ml solution followed by a 30mg injection of MTD201. Another 14 subjects will undergo the same procedures this week to complete the dosing phase of the clinical trial.

Sources cite that after completion of the dosing period, all subjects will undergo a 63-day sampling and observation period. Topline results are expected by the end of the last quarter of 2019 or early in the first quarter of 2020.

For a record, Midatech Pharma is working towards developing therapies using three novel delivery mechanisms as Q-Sphera , MidaCore, MidaSolve. These technologies are focused on enhancing the delivery and distribution of medicines in the body and are useful in exerting their actions in an effective, precise and safe manner.

MTD201 uses Q-Sphera, a polymer microsphere innovation that is used to control and prolong the release of therapeutics over a long period -from weeks to months. Midatech is also working with its clinical trial of MTX110 for patients who are suffering from brain cancer.

About the company

Midatech is a research and development pharmaceutical company that is focused on extending and enhancing the lives of patients who are suffering from rare and serious cancers. The company has created niche in this space by applying and developing novel drug delivery technologies to enhance existing or develop new therapies for serious diseases.

Source Credit - https://www.proactiveinvestors.co.uk/companies/news/904348/midatech-pharma-starts-phase-1-trial-of-hormonal-cancer-treatment-904348.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Deciphera to present data from DCC-3014 trial at CTOS annual meet
Deciphera to present data from DCC-3014 trial at CTOS annual meet
By Mateen Dalal

The ongoing clinical trial of DCC-3014 have shown preliminary anti-tumor activity.    DCC-3014 validates emerging tolerability profile with no Grade 3 or Higher TEAEs.   Encore presentation of data from the INVICTUS Pivotal Phase...

Roches risdiplam meets primary endpoint results in phase 3 trial
Roches risdiplam meets primary endpoint results in phase 3 trial
By Mateen Dalal

Spinal muscular atrophy (SMA) is a genetic neuromuscular condition, affecting approx. 1 in 6,000 babies born globally each year. Numerous healthcare companies throughout the world are putting their best foot forward to develop an effective ...

Disney+ all set for a March 2020 launch in the United Kingdom
Disney+ all set for a March 2020 launch in the United Kingdom
By Mateen Dalal

The entertainment behemoth is launching its much-awaited streaming platform.   Release of more than 300 movies is on the cards. Disney has finally asserted that new streaming service Disney+ will be rolled out soon in the U.K. Disney+ goes...